Multiple Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MK-1029 or Placebo in Patients With Mild to Moderate Asthma.
Phase of Trial: Phase I
Latest Information Update: 02 Feb 2016
At a glance
- Drugs MK 1029 (Primary)
- Indications Asthma
- Focus Adverse reactions
- Sponsors Merck
- 10 Apr 2012 Actual initiation date changed from Jul 2011 to Jun 2011 as reported by ClinicalTrials.gov.
- 26 Jan 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 16 Dec 2011 Planned end date changed from 1 Oct 2011 to 1 Dec 2011 as reported by ClinicalTrials.gov.